The liberty cap mushroom, notoriously used illegally as a psychoactive drug, could be the inspiration for a new therapy for depression according to the US drug regulator.
Johnson & Johnson is “confident” about regulatory reviews of its depression drug esketamine ahead of a likely grilling by FDA experts – even though two of the five trials it is relying
Roche’s diabetes arm is working with Ieso Digital Health to test the Cambridge, UK-based digital therapeutics firm’s mental health programme in type 2 diabetes patients in the UK and Irelan